Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds
- PMID: 25362181
- DOI: 10.4049/jimmunol.1301769
Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds
Abstract
Adoptive transfer of Ag-specific T lymphocytes is an attractive form of immunotherapy for cancers. However, acquiring sufficient numbers of host-derived tumor-specific T lymphocytes by selection and expansion is challenging, as these cells may be rare or anergic. Using engineered T cells can overcome this difficulty. Such engineered cells can be generated using a chimeric Ag receptor based on common formats composed from Ag-recognition elements such as αβ-TCR genes with the desired specificity, or Ab variable domain fragments fused with T cell-signaling moieties. Combining these recognition elements are Abs that recognize peptide-MHC. Such TCR-like Abs mimic the fine specificity of TCRs and exhibit both the binding properties and kinetics of high-affinity Abs. In this study, we compared the functional properties of engineered T cells expressing a native low affinity αβ-TCR chains or high affinity TCR-like Ab-based CAR targeting the same specificity. We isolated high-affinity TCR-like Abs recognizing HLA-A2-WT1Db126 complexes and constructed CAR that was transduced into T cells. Comparative analysis revealed major differences in function and specificity of such CAR-T cells or native TCR toward the same antigenic complex. Whereas the native low-affinity αβ-TCR maintained potent cytotoxic activity and specificity, the high-affinity TCR-like Ab CAR exhibited reduced activity and loss of specificity. These results suggest an upper affinity threshold for TCR-based recognition to mediate effective functional outcomes of engineered T cells. The rational design of TCRs and TCR-based constructs may need to be optimized up to a given affinity threshold to achieve optimal T cell function.
Copyright © 2014 by The American Association of Immunologists, Inc.
Similar articles
-
Avidity characterization of genetically engineered T-cells with novel and established approaches.BMC Immunol. 2016 Jul 13;17(1):23. doi: 10.1186/s12865-016-0162-z. BMC Immunol. 2016. PMID: 27411667 Free PMC article.
-
Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.J Immunother Cancer. 2019 Nov 5;7(1):284. doi: 10.1186/s40425-019-0773-z. J Immunother Cancer. 2019. PMID: 31690351 Free PMC article.
-
Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.J Immunol. 2003 Sep 1;171(5):2197-207. doi: 10.4049/jimmunol.171.5.2197. J Immunol. 2003. PMID: 12928363
-
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.Trends Pharmacol Sci. 2016 Mar;37(3):220-230. doi: 10.1016/j.tips.2015.11.004. Epub 2015 Dec 17. Trends Pharmacol Sci. 2016. PMID: 26705086 Free PMC article. Review.
-
Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419. Int Rev Immunol. 2015. PMID: 25901860 Review.
Cited by
-
Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.J Immunother Cancer. 2022 Mar;10(3):e004035. doi: 10.1136/jitc-2021-004035. J Immunother Cancer. 2022. PMID: 35338087 Free PMC article.
-
Opportunities and Challenges for Antibodies against Intracellular Antigens.Theranostics. 2019 Oct 15;9(25):7792-7806. doi: 10.7150/thno.35486. eCollection 2019. Theranostics. 2019. PMID: 31695801 Free PMC article. Review.
-
TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.JCI Insight. 2018 Feb 22;3(4):e97805. doi: 10.1172/jci.insight.97805. eCollection 2018 Feb 22. JCI Insight. 2018. PMID: 29467338 Free PMC article.
-
Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.J Clin Invest. 2020 May 1;130(5):2673-2688. doi: 10.1172/JCI130562. J Clin Invest. 2020. PMID: 32310221 Free PMC article.
-
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.Oncoimmunology. 2020 Jan 9;9(1):1703449. doi: 10.1080/2162402X.2019.1703449. eCollection 2020. Oncoimmunology. 2020. PMID: 32002302 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials